- Home
- NXG vs SLP Comparison
NXG vs SLP Comparison
Compare NXG & SLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NXG | SLP |
|---|---|---|
| Founded | 2012 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | EDP Services |
| Sector | | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 336.8M | 320.9M |
| IPO Year | 2010 | 1996 |
Fundamental Metrics
Financial Performance| Metric | NXG | SLP |
|---|---|---|
| Price | $58.62 | $15.30 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $24.00 |
| AVG Volume (30 Days) | 116.9K | ★ 266.2K |
| Earning Date | 01-01-0001 | 04-09-2026 |
| Dividend Yield | ★ 14.78% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.26 |
| Revenue | N/A | ★ $59,577,000.00 |
| Revenue This Year | N/A | $3.80 |
| Revenue Next Year | N/A | $5.90 |
| P/E Ratio | ★ N/A | $58.50 |
| Revenue Growth | N/A | ★ 10.52 |
| 52 Week Low | $45.05 | $11.09 |
| 52 Week High | $60.84 | $32.52 |
Technical Indicators
Market Signals| Indicator | NXG | SLP |
|---|---|---|
| Relative Strength Index (RSI) | 57.81 | 57.45 |
| Support Level | $47.61 | $13.95 |
| Resistance Level | $60.84 | $15.59 |
| Average True Range (ATR) | 1.16 | 1.03 |
| MACD | -0.24 | 0.01 |
| Stochastic Oscillator | 54.31 | 48.21 |
Price Performance
Historical ComparisonAbout NXG NXG NextGen Infrastructure Income Fund of Beneficial Interest
Cushing NextGen Infrastructure Income Fund is a closed-end management investment company. Its investment objective is to seek a high total return with an emphasis on current income. The fund invests at least 80% of its net assets in a portfolio of equity and debt securities of infrastructure companies, including energy infrastructure companies, industrial infrastructure companies, sustainable infrastructure companies and technology and communication infrastructure companies.
About SLP Simulations Plus Inc.
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.